Telomir Pharmaceuticals, Inc. (TELO) Q1 2025 Earnings
TELO·Reported May 14, 2025·Before market open
Diluted EPS came in at $-0.07 (+69.6% YoY), beat the $-0.10 consensus by $0.03.
Diluted EPS
$-0.07beat by $0.03
Consensus: $-0.10
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about Telomir Pharmaceuticals, Inc.'s Q1 2025 earnings report.
Telomir Pharmaceuticals, Inc. (TELO) reported Q1 2025 earnings on May 14, 2025 before market open.
Telomir Pharmaceuticals, Inc. reported diluted EPS of $-0.07 for Q1 2025.
EPS beat the consensus estimate of $-0.10 by $0.03.
Compared to the same quarter a year prior, diluted EPS grew 69.6% from $-0.23.
You can read the 10-Q periodic report (0001641172-25-010298) directly on SEC EDGAR. The filing index links above go to sec.gov.